We are live on ! Find out more
AMED

Amedisys

Delisted

AMED was delisted on the 14th of August, 2025.

288 hedge funds and large institutions have $3.07B invested in Amedisys in 2022 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 106 increasing their positions, 109 reducing their positions, and 71 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% more ownership

Funds ownership: 92.87%92.87% (+0.01%)

3% less repeat investments, than reductions

Existing positions increased: 106 | Existing positions reduced: 109

12% less funds holding

Funds holding: 328288 (-40)

41% less capital invested

Capital invested by funds: $5.19B → $3.07B (-$2.11B)

46% less first-time investments, than exits

New positions opened: 38 | Existing positions closed: 71

48% less call options, than puts

Call options by funds: $18.4M | Put options by funds: $35.3M

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
288
Holders Change
-40
Holders Change %
-12.2%
% of All Funds
4.85%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
38
Increased
106
Reduced
109
Closed
71
Calls
$18.4M
Puts
$35.3M
Net Calls
-$17M
Net Calls Change
-$21.4M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$410M +$843K +6,596 +0.2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$319M -$2.38M -18,592 -0.6%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$256M +$71.9M +562,926 +30%
JP Morgan Chase
4
JP Morgan Chase
New York
$177M +$38.6M +301,899 +22%
RP
5
Riverbridge Partners
Minnesota
$158M -$24.1M -188,669 -11%
Ameriprise
6
Ameriprise
Minnesota
$124M -$43.7M -342,438 -23%
State Street
7
State Street
Massachusetts
$89.5M -$2.53M -19,767 -2%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$78.4M -$21.5M -168,412 -18%
Bank of New York Mellon
9
Bank of New York Mellon
New York
$62.7M +$2.29M +17,953 +3%
BG
10
Bellevue Group
Switzerland
$61.5M +$1.15M +9,023 +2%
Ensign Peak Advisors
11
Ensign Peak Advisors
Utah
$60.2M +$45.7M +357,598 +166%
Capital Research Global Investors
12
Capital Research Global Investors
California
$57.5M
CS
13
Credit Suisse
Switzerland
$53.4M +$1.03M +8,073 +2%
Schroder Investment Management Group
14
Schroder Investment Management Group
United Kingdom
$50.6M +$9.32M +72,956 +18%
American Century Companies
15
American Century Companies
Missouri
$48M +$14.6M +113,972 +33%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$46.3M +$583K +4,563 +1%
Allspring Global Investments
17
Allspring Global Investments
North Carolina
$45.6M -$954K -7,465 -2%
FCM
18
Frontier Capital Management
Massachusetts
$41.4M +$6.74M +52,736 +15%
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$39.1M +$2.65M +20,704 +6%
Northern Trust
20
Northern Trust
Illinois
$38.7M -$2.46M -19,261 -5%
Westfield Capital Management
21
Westfield Capital Management
Massachusetts
$33.7M +$3.4M +26,639 +9%
Charles Schwab
22
Charles Schwab
California
$33.2M +$1.69M +13,237 +4%
Principal Financial Group
23
Principal Financial Group
Iowa
$32.4M -$1.62M -12,680 -4%
Norges Bank
24
Norges Bank
Norway
$29.9M +$1.82M +14,256 +5%
Amundi
25
Amundi
France
$27.5M +$618K +4,835 +2%

AMED Hedge Fund Activity: Q2 2022 in Review

288 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q2 2022, worth a combined $3.07B — down 41% from $5.19B a quarter earlier.

Sellers outnumbered buyers: 71 funds closed out of AMED and 38 opened new positions — a net loss of 33 holders — while 109 trimmed existing stakes and 106 added.

The largest buyer was Wellington Management Group, adding an estimated $71.9M. The largest seller was William Blair Investment Management, exiting entirely with an estimated $124M sold.

  • 288 institutional investors held Amedisys (AMED) as of Q2 2022, down from 328 in Q1 2022.
  • Funds reported $3.07B of Amedisys stock for Q2 2022, down 41% quarter-over-quarter.
  • 38 funds opened new Amedisys positions in Q2 2022 and 71 closed out, a net change of -33 holders.
  • The largest Amedisys buyer in Q2 2022 was Wellington Management Group, an estimated $71.9M added.
  • The largest Amedisys seller in Q2 2022 was William Blair Investment Management, an estimated $124M sold.

Based on aggregated 13F filings for Q2 2022.